Nexplanon: The new implant for long-term contraception. A comprehensive descriptive review

Department of Obstetrics & Gynaecology, University "Magna Graecia" of Catanzaro, Viale Europa, Catanzaro, Italy.
Gynecological Endocrinology (Impact Factor: 1.33). 02/2012; 28(9):710-21. DOI: 10.3109/09513590.2011.652247
Source: PubMed


Nexplanon(®) is a new long-term reversible contraception method. The current review is aimed to analyze the published data concerning the contraceptive effectiveness of Nexplanon(®) and its effects on reproductive function. Pharmacological properties and technical procedures of insertion and removal, as well as the efficacy and safety data available, were discussed. Possible strategies for treating Nexplanon(®)-related bleeding were also described. With regard to the future research and the future scientific developments of contraceptive implants, the possible use of Nexplanon(®) wide-ranging for the symptomatic treatment of endometriosis and premenstrual syndrome (PMS) were considered. Finally, it was defined in which women the use of Nexplanon(®) is indicated and in which it is contra-indicated.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The etonogestrel contraceptive implant (Implanon®) is an effective, long-acting subdermal method of hormonal contraception for women. We describe a case of forearm pain and hypoesthesia associated with the insertion of the Implanon® contraceptive implant in a healthy 26-year-old female. These symptoms were due to direct implant contact with the medial cutaneous nerve of the forearm. The importance of correct insertion technique is discussed. Care should be taken to avoid nerve injury during insertion of subdermal contraceptive implants. An understanding of regional anatomy and the correct insertion technique will prevent insertion-related complications. Nexplanon® has been developed to replace Implanon®. It has a redesigned applicator intended to increase insertion accuracy.
    No preview · Article · Jul 2012 · Contraception
  • [Show abstract] [Hide abstract]
    ABSTRACT: The first hormonal pill, called Enovid(®), was approved by the Federal Drug Administration (FDA) in May 1960. It contained mestranol and norethisterone. Over the years, oral contraceptives have evolved through gradual lowering of ethinyl estradiol (EE) content, introduction of 17β estradiol, and many different progestins. The standard regimen allows for 21 days of pill containing steroids and a pill-free interval of 7 days. Recently, continuous or extended regimens have been approved. In order to improve compliance, alternative routes of combined oral contraceptive (COC) administration have been developed such as vaginal or transdermal routes. In 2009, according to the United Nations, the mean global percentage using contraception in women who are married or in union was 62.7%. COC represented 8.8% of contraceptive prevalence, reaching 15.4% in more developed countries. More than 100 million women worldwide use COCs. However, each year, many unintended pregnancies occur, indicating that contraception still needs to be promoted.
    No preview · Article · Feb 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Desogestrel (DSG) is a third-generation progestin. It is commonly used in various formulations for hormonal contraception including combinations with ethinyl estradiol (EE), progestin-only pill and subdermal implants. DSG is also used in menopausal patients for hormone replacement therapy (HRT). Areas covered: The current manuscript aims to review the available data on safety and tolerability of DSG in oral contraception and HRT. The material included in the manuscript was searched and obtained via Medline, PubMed and EMBASE up to September 2012 using the search terms 'adverse events, side effects, tolerability' in combination with 'desogestrel and progestins'. Expert opinion: DSG is frequently used as contraceptive and it shows good contraceptive efficacy as demonstrated by the Pearl indexes reported in the studies reviewed in this manuscript. It is a versatile compound; in fact, it can be used either as progestin-only contraceptive or in combination with EE, and different formulations are available (such as the subdermal implant). In contraception, DSG is generally well tolerated but its use is associated with doubled risk of venous thromboembolism compared to second-generation progestins. Although DSG is efficacious in HRT, it may not represent the best choice due to the potential higher risk of breast cancer compared with progesterone or dydrogesterone.
    No preview · Article · Apr 2013 · Expert Opinion on Drug Safety
Show more